^
    1d
    A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm. (PubMed, Am J Hematol)
    The CCDC6::JAK2 chimeric protein retains the CCDC6 coiled-coil domain and the JAK2 kinase domain. Dimerization of chimeric proteins through coiled-coil domains promotes JAK2 autophosphorylation leading to constitutive activation of the JAK/STAT signaling pathway.
    Journal
    |
    JAK2 (Janus kinase 2) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    Jakafi (ruxolitinib)
    2d
    Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias. (PubMed, Adv Sci (Weinh))
    Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance...Moreover, through a compound screen, followed by chemical proteomics and compound optimization, WWQ-03-012 is discovered, which selectively degrades mutant JAK2, induces primary leukemia cells death, and inhibits MPN progression through targeting DESI2 enzymatic activity in vitro and in vivo. These studies provide a novel therapeutic strategy against mutated JAK2 signaling in MPN and sAML.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    8d
    RUX-HAPLO: Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Colorado, Denver
    New P1/2 trial
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    9d
    CINC424C2416: Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease (clinicaltrials.gov)
    P4, N=36, Recruiting, Novartis Pharmaceuticals | N=54 --> 36
    Enrollment change
    |
    Jakafi (ruxolitinib)
    10d
    AURORA: Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (clinicaltrials.gov)
    P2, N=66, Recruiting, ReAlta Life Sciences, Inc. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib)
    10d
    HEMA-MED: A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (clinicaltrials.gov)
    P1/2, N=26, Recruiting, iOnctura | Initiation date: May 2025 --> Nov 2025
    Trial initiation date
    |
    Jakafi (ruxolitinib) • roginolisib (IOA-244)
    11d
    JAK1/2 Inhibition Delays Cachexia and Improves Survival through Increased Food Intake. (PubMed, bioRxiv)
    We show that JAK inhibition by ruxolitinib restores weight, fat mass, and prolongs survival in murine models of lung cancer. These effects were independent of tumor burden, underscoring the relevance of addressing cachexia to improve survival in cancer patients and supporting clinical testing of JAK inhibition for cancer cachexia.
    Journal
    |
    IL6 (Interleukin 6) • JAK1 (Janus Kinase 1) • LEP (Leptin)
    |
    Jakafi (ruxolitinib)
    14d
    APTBCy: Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (clinicaltrials.gov)
    P2, N=60, Recruiting, St. Petersburg State Pavlov Medical University
    New P2 trial
    |
    Jakafi (ruxolitinib) • cyclophosphamide
    15d
    A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (clinicaltrials.gov)
    P3, N=340, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Sep 2026 --> Jul 2027
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • hydroxyurea • busulfan • bomedemstat (MK-3543)
    15d
    Splenic Artery Aneurysm Associated with Myelofibrosis Managed by Coil Embolization. (PubMed, Intern Med)
    Ruxolitinib therapy markedly reduced splenomegaly and improved constitutional symptoms, thereby optimizing hemodynamic conditions and overall status for safe spleen-preserving coil embolization. This case highlights the potential relationship between MF and aneurysm formation while demonstrating that concomitant JAK inhibitor therapy may facilitate safe endovascular treatment in select patients.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    16d
    A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis (clinicaltrials.gov)
    P1, N=18, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib) • Jakafi (ruxolitinib)